Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18729182 | 0.84 | CD274 (0.51) | CD274PDCD1HTR1AADRA1DADRA1A | |
| SCHEMBL18757374 | 0.83 | CD274 (0.48) | CD274PDCD1 | |
| SCHEMBL18728568 | 0.82 | CD274 (0.50) | CD274PDCD1HTR1AADRA1DADRA1A | |
| SCHEMBL28596509 | 0.81 | CD274 (0.43) | CD274PDCD1 | |
| SCHEMBL30267183 | 0.81 | CD274 (0.43) | CD274PDCD1 | |
| SCHEMBL19897862 | 0.81 | CD274 (0.59) | CD274PDCD1 | |
| SCHEMBL19911749 | 0.79 | CD274 (0.57) | CD274PDCD1 | |
| SCHEMBL18729012 | 0.78 | CD274 (0.49) | CD274PDCD1 | |
| SCHEMBL18729013 | 0.78 | CD274 (0.49) | CD274PDCD1 | |
| SCHEMBL20721089 | 0.73 | CD274 (0.47) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4332099-A1 | NOVEL BIPHENYL DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | Xi'an Xintong Pharmaceutical Research Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20240043392-A1 | NOVEL BIPHENYL DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | XI'AN XINTON PHARMACEUTCAL RESEARCH CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043392-A1 | NOVEL BIPHENYL DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885HTR1A 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.